Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit of TIVICAY in the indication “treatment of Human Immunodeficiency Virus (HIV)-infected adults and adolescents above 12 years of age” is substantial in antiretroviral naïve patients and in experienced patients with prior treatment failure. |
Clinical Added Value
| moderate |
In patients who have no therapeutic options and whose virus is susceptible to dolutegravir :
The Transparency Committee considers that TIVICAY (dolutegravir), in combination with an optimised background regimen, provides a moderate improvement in actual benefit (level III) in terms of immunological and virological efficacy in therapeutic management. |
| minor |
In antiretroviral-naïve or experienced patients whose virus does not have integrase inhibitor (INI) resistance mutations :
The Transparency Committee considers that TIVICAY (dolutegravir) incombination with other antiretrovirals provides a minor improvement in actual benefit (level IV) compared with raltegravir (ISENTRESS) due to having an immunological and virological efficacy that is not inferior to that of raltegravir with a higher genetic barrier to the development of resistance and better ease of use than raltegravir (a single dose versus two daily doses in the case of raltegravir). |
See also
HAS opinions and decisions
05/03/2014
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
TF6TTKrNUKdQhr40
Listen
